Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Summit Therapeutics (SMMT) Remains an Under-the-Radar DMD Play to Watch - Oppenheimer
December 18, 2015 12:57 PM ESTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $28 price target on Summit Therapeutics plc (NASDAQ: SMMT), saying the stock remains an under-the-radar DMD play.
Marai commented, "On 12/17, Summit reported F3Q15 results, ending the quarter with £22.2M in cash. Given its... More
